激素治疗在前列腺癌管理中的应用：循证方法。
Hormone therapy in the management of prostate cancer: evidence-based approaches.
机构信息
Chairman, Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, 1025 Walnut Street, Suite 1112, Philadelphia, PA 19107, USA.
出版信息
Ther Adv Urol. 2010 Aug;2(4):171-81. doi: 10.1177/1756287210375270.
Abstract
Hormonal therapy has been the standard for advanced prostate cancer for over 60 years. Recently, the utility of androgen ablation through various means has been demonstrated for earlier stages of disease. In particular, the strongest evidence to date involves the use of hormonal therapy in combination with radiation therapy. In this article we review the basic concepts in hormonal ablation for prostate cancer and review the evidence-based studies that support the use of hormonal therapy in early stage prostate cancer.
摘要
激素治疗已经成为 60 多年来治疗晚期前列腺癌的标准方法。最近，通过各种手段进行雄激素阻断的方法在疾病早期阶段的应用也得到了证实。特别是，迄今为止最有力的证据涉及到联合使用激素治疗和放射治疗。在本文中，我们回顾了前列腺癌激素消融的基本概念，并回顾了支持在早期前列腺癌中使用激素治疗的基于证据的研究。
相似文献
1
Hormone therapy in the management of prostate cancer: evidence-based approaches.
Ther Adv Urol. 2010 Aug;2(4):171-81. doi: 10.1177/1756287210375270.
2
Medical therapy of prostate cancer. A review.
Minerva Urol Nefrol. 2005 Jun;57(2):71-84.
3
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
4
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
5
The selection of hormonal therapy in prostate cancer: who, when, and for how long?
J Natl Compr Canc Netw. 2004 May;2(3):261-8. doi: 10.6004/jnccn.2004.0023.
6
Endocrine treatment of prostate cancer.
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
7
Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
Cochrane Database Syst Rev. 2020 Dec 12;12(12):CD013245. doi: 10.1002/14651858.CD013245.pub2.
8
Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
Urology. 2003 Dec 29;62 Suppl 1:141-6. doi: 10.1016/j.urology.2003.09.006.
9
Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.
Exp Hematol Oncol. 2016 Jun 22;5:15. doi: 10.1186/s40164-016-0046-1. eCollection 2015.
10
Recent advances in hormonal therapy for advanced prostate cancer.
Oncology (Williston Park). 2003 Aug;17(8):1047-52; discussion 1054-8.
引用本文的文献
1
Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort.
Prostate. 2025 Sep;85(12):1077-1086. doi: 10.1002/pros.24913. Epub 2025 Jun 11.
2
Exercise May Improve Completion of Standard and Emerging Cancer Treatments.
Exerc Sport Sci Rev. 2025 Jul 1;53(3):110-124. doi: 10.1249/JES.0000000000000360. Epub 2025 Feb 18.
3
Breaking the silence: The role of extracellular vesicles in unraveling the diagnosis and treatment of endometriosis.
Extracell Vesicles Circ Nucl Acids. 2023 Dec 4;4(4):599-614. doi: 10.20517/evcna.2023.43. eCollection 2023.
4
The multifaceted role of extracellular vesicles in prostate cancer-a review.
Cancer Drug Resist. 2023 Jul 28;6(3):481-498. doi: 10.20517/cdr.2023.17. eCollection 2023.
5
Correlation Between Serum Prostate-Specific Antigen and Testosterone Following Bilateral Total Orchidectomy for Patients with Advanced Prostate Cancer in Jos, Nigeria.
J West Afr Coll Surg. 2023 Apr-Jun;13(2):82-89. doi: 10.4103/jwas.jwas_274_22. Epub 2023 Mar 20.
6
Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.
PLoS One. 2023 Mar 9;18(3):e0282646. doi: 10.1371/journal.pone.0282646. eCollection 2023.
7
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Int J Mol Sci. 2021 Nov 15;22(22):12330. doi: 10.3390/ijms222212330.
8
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models).
Int J Mol Sci. 2021 Nov 14;22(22):12297. doi: 10.3390/ijms222212297.
9
TLX, an Orphan Nuclear Receptor With Emerging Roles in Physiology and Disease.
Endocrinology. 2021 Nov 1;162(11). doi: 10.1210/endocr/bqab184.
10
Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China.
Chin J Cancer Res. 2019 Jun;31(3):511-520. doi: 10.21147/j.issn.1000-9604.2019.03.13.
本文引用的文献
1
Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
Prostate Cancer Prostatic Dis. 2009;12(4):333-8. doi: 10.1038/pcan.2009.35. Epub 2009 Sep 1.
2
Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.
J Biomed Biotechnol. 2009;2009:625394. doi: 10.1155/2009/625394. Epub 2009 Oct 22.
3
Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.
Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049. Epub 2009 Aug 7.
4
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
BJU Int. 2010 Jan;105(2):185-90. doi: 10.1111/j.1464-410X.2009.08698.x. Epub 2009 Jul 8.
5
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
Cancer. 2009 Aug 1;115(15):3437-45. doi: 10.1002/cncr.24395.
6
Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.
Urol Oncol. 2011 Jan-Feb;29(1):52-7. doi: 10.1016/j.urolonc.2009.03.024. Epub 2009 Jun 12.
7
Duration of androgen suppression in the treatment of prostate cancer.
N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.
8
Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials.
Cancer Treat Rev. 2009 Nov;35(7):540-6. doi: 10.1016/j.ctrv.2009.05.001. Epub 2009 Jun 2.
9
Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
Prostate Cancer Prostatic Dis. 2009;12(3):233-40. doi: 10.1038/pcan.2009.12. Epub 2009 Jun 2.
10
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Eur Urol. 2009 Jun;55(6):1269-77. doi: 10.1016/j.eururo.2009.02.016. Epub 2009 Feb 21.
Zotero 插件